(Press-News.org) CHICAGO – Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA.
Certain serogroup B Neisseria meningitidis (MenB) vaccines proved effective in clinical trials and controlled a clonal MenB outbreak in New Zealand; however, the high strain specificity of these vaccines limited their usefulness, especially in infants and young children, according to background information in the article.
Nicoletta Gossger, M.D., of the University of Oxford, United Kingdom, and colleagues assessed the immunogenicity (the ability to produce an immune response) and reactogenicity (producing adverse reactions) of a vaccine developed to provide broader protection, a multicomponent serogroup B meningococcal vaccine (4CMenB), in a large group of infants, given in 2 different schedules, with or separately from routine vaccines. The multicenter, randomized controlled study included 1,885 infants enrolled at age 2 months from August 2008 to July 2010 in Europe. Participants were randomized to receive (1) 4CMenB at 2, 4, and 6 months with routine vaccines (7-valent pneumococcal and combined diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B, Haemophilus influenzae type b vaccines); (2) 4CMenB at 2, 4, and 6 months and routine vaccines at 3, 5, and 7 months; (3) 4CMenB with routine vaccines at 2, 3, and 4 months; or (4) routine vaccines alone at 2, 3, and 4 months. The primary outcome the researchers measured was the percentage of participants with human complement serum bactericidal activity (hSBA) titer (concentration) of 1:5 or greater against 3 MenB strains specific for vaccine antigens (NZ98/254, 44/76-SL, and 5/99).
After immunization with 4CMenB and routine vaccines together at either 2, 4, and 6 or 2, 3, and 4 months, 99 percent or more of participants had hSBA titers of 1:5 or greater for strains 44/76-SL and 5/99. For NZ98/254, this proportion was 79 percent for vaccination at 2, 4, and 6 months with routine vaccines, 86.1 percent for vaccination at 2, 4, and 6 months without routine vaccines, and 81.7 percent for vaccination at 2,3, and 4 months with routine vaccines. The predefined criteria of a sufficient immune response was met for all three strains.
Responses to routine vaccines given with 4CMenB were noninferior (outcome not worse than treatment compared to) to routine vaccines alone for all antigens, except for the responses to pertactin (a pertussis antigen) and the pneumococcal vaccine serotype 6B.
"Fever was seen following 26 percent to 41 percent of 4CMenB doses when administered alone, compared with 23 percent to 36 percent after routine vaccines given alone and 51 percent to 61 percent after 4CMenB and routine vaccines administered together," the authors write.
"In conclusion, 4CMenB was immunogenic, generally well tolerated, and showed minimal interference with routine vaccines in the first year of life. The flexibility in schedule allows it to be incorporated into a range of country-specific immunization schedules and for primary immunization to be completed in early infancy. If licensed, the decisions regarding vaccine introduction will require detailed assessment of potential vaccine coverage at a regional level and monitoring after implementation to determine the accuracy of such predictions. Nevertheless, this vaccine could potentially provide improved protection for infants against meningococcal disease beyond the protection provided by currently licensed vaccines."
(JAMA. 2012;307[6]:573-582. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: This study was funded by Novartis Vaccines and Diagnostics. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Editorial: Inching Toward a Serogroup B Meningococcal Vaccine for Infants
In an accompanying editorial, Amanda C. Cohn, M.D., and Nancy E. Messonnier, M.D., of the Centers for Disease Control and Prevention, Atlanta, write that "the potential of 4CMenB vaccine to reduce serogroup B meningococcal disease is substantial, but it cannot be compared with the success of conjugate vaccine programs."
"4CMenB vaccine may not reduce nasopharyngeal [pertaining to the cavity of the nose and the nasal parts of the pharynx] carriage or produce herd immunity, as the serogroup C conjugate vaccine did in the United Kingdom. Booster doses may be required to sustain protection but may not confer the same degree of immunologic memory as conjugate vaccines. Countries will have to weigh the benefits of serogroup B vaccination against the costs of adding vaccines to the infant schedule. However, the anticipated licensure of this vaccine in Europe and other countries means that for the first time vaccines to prevent all 5 of the serogroups that cause most meningococcal disease worldwide will be available."
(JAMA. 2012;307[6]:614-615. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
###
To contact corresponding author Matthew D. Snape, M.D., F.R.C.P.C.H., email matthew.snape@paediatrics.ox.ac.uk. To contact editorial co-author Amanda C. Cohn, M.D., call Tom Skinner at 404-639-3286 or email TSkinner@cdc.gov.
END
CHICAGO – Among postmenopausal women with hormone receptor-positive breast cancer, increasing age was associated with a higher risk of death from breast cancer, according to a study in the February 8 issue of JAMA.
"Breast cancer is the leading contributor to cancer incidence and cancer mortality in women worldwide, with 1,383,500 new cases in 2008. In the United States in 2008, 41 percent of these women were aged 65 years or older at diagnosis. Because breast cancer incidence increases with increasing age, changing demographics and continuously increasing life expectancy ...
CHICAGO – Although some data have suggested a possible increased risk of intussusception (when a portion of the small or large intestine slides forward into itself, like a telescope) after administration of the pentavalent rotavirus vaccine in infants, an analysis that included almost 800,000 doses administered to U.S. infants found no increased risk of this condition following vaccination, according to a study in the February 8 issue of JAMA.
"In 1999, the rhesus tetravalent rotavirus vaccine (RRV, Rotashield) was withdrawn from the U.S. market due to a significantly ...
CHICAGO – Short-term use of the antibiotic cefpodoxime for the treatment of women with uncomplicated cystitis (bladder infection) did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin, a drug in the fluoroquinolone class of antibiotics for which there have been concerns about overuse and a resulting increase in resistance rates, according to a study in the February 8 issue of JAMA. The criteria for noninferiority was if the efficacy of cefpodoxime had been shown to be within a pre-specified margin of 10 percent of the efficacy ...
For all those who have wondered where they'd be without their mothers, a study reported in the February Cell Metabolism, a Cell Press publication, puts a whole new spin on the question. Mice whose mothers pass along a mutant copy of a single imprinted gene can't keep themselves warm and die soon after leaving the comfort of the nest. The findings also reveal that the babies require a second round of heat-generating brown fat to survive.
"When that second wave is delayed, it gets them in the end," said Anne Ferguson-Smith of the University of Cambridge.
The findings ...
BUFFALO, N.Y. -- Parkinson's disease researchers at the University at Buffalo have discovered how mutations in the parkin gene cause the disease, which afflicts at least 500,000 Americans and for which there is no cure.
The results are published in the current issue of Nature Communications.
The UB findings reveal potential new drug targets for the disease as well as a screening platform for discovering new treatments that might mimic the protective functions of parkin. UB has applied for patent protection on the screening platform.
"This is the first time that human ...
The aviation accident attorneys at Baum, Hedlund, Aristei & Goldman are representing the families of the two men killed in Robinson Helicopter Company's first R66 crash which occurred on July 12, 2011 near Flandes, Colombia.
Jose Ricardo Cabrera Killed in the crash, was the owner of the R66 aircraft, Juan Pablo Gaviria, former president of the Colombian Civil Air Patrol, and Jose Ricardo Cabrera, his dear friend and a skilled helicopter pilot.
The R66 crashed shortly after take-off from Girardot Airport in Colombia. According to the National Transportation Safety ...
HOUSTON -- (Feb. 8, 2012) -- A protein kinase known as ROCK1 can exacerbate an important process called fission in the mitochondria, the power plants of cells, leading to diabetic kidney disease, said researchers from Baylor College of Medicine in a report that appears online today in the journal Cell Metabolism. (ROCK1 stands for (Rho-associated coiled-coil containing protein kinase 1.)
"We have shown the connection between ROCK1 and the progression to kidney disease through the effect of ROCK1 on the mitochondria," said Dr. Farhad R. Danesh, association professor ...
Visitors to Statuary Hall in the U.S. Capitol Building may have experienced a curious acoustic feature that allows a person to whisper softly at one side of the cavernous, half-domed room and for another on the other side to hear every syllable. Sound is whisked around the semi-circular perimeter of the room almost without flaw. The phenomenon is known as a whispering gallery.
In a paper published in Nature Communications, a team of engineers at Stanford describes how it has created tiny hollow spheres of photovoltaic nanocrystalline-silicon and harnessed physics to do ...
While epilepsy surgery is a safe and effective intervention for seizure control, medical therapy remains the more prominent treatment option for those with epilepsy. However, a new 26-year study reveals that following epilepsy surgery, nearly half of participants were free of disabling seizures and 80% reported better quality of life than before surgery. Findings from this study—the largest long-term study to date—are now available in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE).
More than 50 million ...
###
Additional authors on the study include: Elie Ghanem, MD and Bahar Adeli, BA, both with the Rothman Institute at Jefferson.
About Thomas Jefferson University Hospitals
Thomas Jefferson University Hospitals (TJUH) are dedicated to excellence in patient care, patient safety and the quality of the healthcare experience. Consistently ranked by U.S. News & World Report among the nation's top hospitals, Thomas Jefferson University Hospital, established in 1825, has over 900 licensed acute care beds with major programs in a wide range of clinical specialties. ...
